Posterior fossa glioblastoma multiforme is a very rare childhood tumor with an extremely poor prognosis. There are only few cases of primary cerebellar glioblastoma described in the literature, and primary cerebellar glioblastoma presenting radiologically as a cerebellopontine angle mass lesion has not been reported previously. The authors report a multicentric glioblastoma multiforme in an 11-year-old child presenting predominantly as a cerebellopontine angle mass lesion, who finally expired 2 months after surgery. The presentation was very bizarre and the diagnosis was made only after histopathology examination.

Keywords:
Cerebellopontine angle, Glioblastoma multiforme, Posterior fossa
1.
Katz DS, Poe LB, Winfield JA Jr, Corona RJ: A rare case of cerebellar glioblastoma multiforme in childhood: MR imaging. Clin Imaging 1995;19:162–164.
2.
Berger MS, Edwards MSB, LaMasters D, Davis RL, Wilson CB: Pediatric brain stem tumors: radiographic, pathological, and clinical correlations. Neurosurgery 1983;12:298–302.
3.
Demir MK, Hakan T, Akinci O, Berkman Z: Primary cerebellar glioblastoma multiforme. Diagn Interv Radiol 2005;11:83–86.
4.
Dohrmann GJ, Dunsmore RH: Glioblastoma multiforme of the cerebellum. Surg Neurol 1975;3:219–223.
5.
Hegedus K, Molnar P: Primary cerebellar glioblastoma multiforme with an unusually long survival. J Neurosurg 1983;58:589–592.
6.
Kopelson G: Cerebellar glioblastoma. Cancer 1982;50:308–331.
7.
Kulkarni AV, Becker LE, Jay V, Armstrong DC, Drake JM: Primary cerebellar glioblastomas multiforme in children. Report of four cases. J Neurosurg 1999;90:546–550.
8.
Levine SA, McKeever PE, Greenberg HS: Primary cerebellar glioblastoma multiforme. J Neurooncol 1987;5:231–236.
9.
Luccarelli G: Glioblastoma multiforme of the cerebellum: description of three cases. Acta Neurochir (Wien) 1980;53:107–116.
10.
Nishio S, Fukui M, Tateishi J: Brain stem gliomas: a clinicopathological analysis of 23 histologically proven cases. J Neurooncol 1988;6:245–250.
11.
Smith RR: Brain stem tumors. Semin Roentgenol 1990;25:249–262.
12.
Tibbs PA, Mortara RH: Primary glioblastoma multiforme of the cerebellum. A case report. Acta Neurochir 1990;52:13–18.
13.
Wisoff HS, Llena JF: Glioblastoma multiforme of the cerebellum five decades after irradiation of a cerebellar tumor. J Neurooncol 1989;7:339–344.
14.
Yang SY, Wang KC, Cho BK, Kim YY, Lim SY, Park SH, Kim IH, Kim SK: Radiation-induced cerebellar glioblastoma at the site of a treated medulloblastoma: case report. J Neurosurg 2005;102(suppl 4):417–422.
15.
Zito JL, Siva A, Smith TW, Leeds M, Davidson R: Glioblastoma of the cerebellum: computed tomographic and pathologic considerations. Surg Neurol 1983;19:373–378.
16.
Chamberlain MC, Silver P, Levin VA: Poorly differentiated gliomas of the cerebellum: a study of 18 patients. Cancer 1990;65:337–340.
17.
Kuroiwa T, Numaguchi Y, Rothman MI, Zoarski GH, Morikawa M, Zagardo MT, et al: Posterior fossa glioblastoma multiforme: MR findings. Am J Neuroradiol 1995;16:583–589.
18.
Salazar OM: Primary malignant cerebellar astrocytoma in children: a signal for postoperative craniospinal irradiation. Int J Radiat Oncol Biol Phys 1981;7:1661–1665.
19.
Shinoda J, Yamada H, Sakai N, Ando T, Hirata T, Hirayama H: Malignant cerebellar astrocytic tumors in children. Acta Neurochir 1989;98:1–8.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.